Compare · KAPA vs NVO
KAPA vs NVO
Side-by-side comparison of Kairos Pharma Ltd. (KAPA) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both KAPA and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 36632.4x KAPA ($5.9M).
- NVO has been more active in the news (9 items in the past 4 weeks vs 3 for KAPA).
- NVO has more recent analyst coverage (25 ratings vs 0 for KAPA).
- Company
- Kairos Pharma Ltd.
- Novo Nordisk A/S
- Price
- $0.24+3.96%
- $48.65+3.65%
- Market cap
- $5.9M
- $215.46B
- 1M return
- -17.94%
- -
- 1Y return
- -79.56%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- AMEX
- NYSE
- IPO
- 2024
- News (4w)
- 3
- 9
- Recent ratings
- 0
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest KAPA
- Kairos Pharma Ltd. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure
- Kairos Pharma Announces 1-for-7 Reverse Stock Split
- SEC Form 10-Q filed by Kairos Pharma Ltd.
- Kairos Pharma Ltd. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
- Kairos Pharma Announces Strategic Collaboration with Bayer to Enhance XOFIGO Activity in Metastatic Prostate Cancer
- Kairos Pharma Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 8-K filed by Kairos Pharma Ltd.
- Kairos Pharma Ltd. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form DEFA14A filed by Kairos Pharma Ltd.
- SEC Form DEF 14A filed by Kairos Pharma Ltd.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S